OptimizeRx (OPRX): Clinical Network Growth Drives 37% Reach Boost Amid Analyst Upgrades
OptimizeRx Corp (NASDAQ:OPRX) is one of the best performing micro cap stocks in 2025.
Optimizerx Corp (OPRX)
Market is closed
Sector: Services-Business Services, Nec
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Whetstone Capital Advisors David Atterbury | 1,508,303 | $30,920,212 | 8.56% | |
| 2. | Royce & Associates Chuck Royce | 677,330 | $13,885,265 | -15% | 0.14% |
| 3. | Parkman Healthcare Partners Greg Martinez | 509,611 | $10,447,026 | +1% | 1.09% |
| 4. | Manatuck Hill Partners Mark Broach | 472,307 | $9,682,294 | +4% | 3.2% |
| 5. | D E Shaw D. E. Shaw | 321,051 | $6,581,546 | -23% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.60 | 321,408 | $2,443,761.45 | 389,452 | 2025-03-14 | Filing | |
| $5.01 | 20,000 | $100,220.00 | 601,253 | 2024-12-12 | Filing | |
| $15.75 | 1,000 | $15,750.00 | 5,000 | 2022-08-26 | Filing | |
| $16.45 | 6,000 | $98,723.40 | 38,660 | 2022-08-19 | Filing | |
| $15.29 | 10,700 | $163,641.52 | 461,772 | 2022-08-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.51 | 1,388 | $18,751.88 | 126,830 | 2025-12-19 | Filing | |
| $18.75 | 1,620 | $30,375.00 | 188,916 | 2025-10-03 | Filing | |
| $17.49 | 11,120 | $194,488.80 | 44,215 | 2025-08-28 | Filing | |
| $15.19 | 4,000 | $60,750.80 | 11,114 | 2024-01-09 | Filing | |
| $44.96 | 400 | $17,984.00 | 445,672 | 2022-02-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,793 | $21,982 | 0% | |
| 2. | 565 | $6,927 | 0% | |
| 3. | 14 | $172 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
9 Best Performing Micro Cap Stocks in 2025
A Bloomberg report published on January 2, 2026, argues that 2025 was an everything rally.
OptimizeRx Corporation (NASDAQ:OPRX) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx's Third Quarter Fiscal Year 2025 Earnings Conference Call. With us today is Chief Executive Officer, Steve Silvestro.
OptimizeRx Corporation (NASDAQ:OPRX) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx's Second Quarter Fiscal 2025 Earnings Conference Call.
OptimizeRx Corporation (NASDAQ:OPRX) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx First Quarter Fiscal 2025 Earnings Conference Call.
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2024 Earnings Call Transcript
Operator: Good morning, everyone, and thank you for joining OptimizeRx's Fourth Quarter and Full Year Fiscal 2024 Earnings Conference Call. With us today is Chief Executive Officer, Steve Silvestro.
OptimizeRx Corporation (NASDAQ:OPRX) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx's Third Quarter Fiscal 2024 Earnings Call. With us today is OptimizeRx's Chief Executive Officer, William Febbo.
OptimizeRx Corporation (NASDAQ:OPRX) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx's Second Quarter Fiscal 2024 Earnings Call. With us today is the Chief Executive Officer of OptimizeRx, William Febbo.
OptimizeRx Corporation (NASDAQ:OPRX) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx's First Quarter Fiscal 2024 Earnings discussion. With us today is the Chief Executive Officer of OptimizeRx, William Febbo.
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call Transcript
Operator: Good morning, everyone and thank you for joining OptimizeRx’s Fourth Quarter Fiscal 2023 Conference Call. With us today is the Chief Executive Officer of OptimizeRx, William Febbo.